Potential23 Mar 2023 17:17
Condiut merger will be sooner than later,most importantly waitinng for Validation update from Corepath. we can move forward on positive report hence Ciz will have access to 22 states with China to look forward to so taking in
assumption that the Cizzle Biotechnology test would cost the NHS £200 (for comparison, a PSA tests costs
£100, and a breast genetic/biomarker test costs £600, and a chest CT scan costs £400), the UK market
potential is £20.7 million p.a. Removing 50 per cent. of the false positives from two-year follow-up would
result in 207,400 fewer chest CT scans being performed, saving the NHS £83.0m, generating net savings
of £62.3 million over a two-year period for the NHS